In NSCLC, METex14 skipping alterations typically do not co-occur with other primary oncogenic drivers, such as EGFR, ALK, ROS1, BRAF, KRAS, ERBB2, or RET (12–14). Here, ERBB2 is linked to non-small cell lung carcinoma.